

2025 Step Therapy Criteria

Updated 10/01/2024

ANTIPSYCHOTICS (ORAL) - PST

Products Affected

- aripiprazole 1 mg/mL oral solution
- aripiprazole 10 mg disintegrating tablet
- aripiprazole 10 mg tablet
- aripiprazole 15 mg disintegrating tablet
- aripiprazole 15 mg tablet
- aripiprazole 2 mg tablet
- aripiprazole 20 mg tablet
- aripiprazole 30 mg tablet
- aripiprazole 5 mg tablet
- asenapine 10 mg sublingual tablet
- asenapine 2.5 mg sublingual tablet
- asenapine 5 mg sublingual tablet
- Caplyta 10.5 mg capsule
- Caplyta 21 mg capsule
- Caplyta 42 mg capsule
- Fanapt 1 mg tablet
- Fanapt 10 mg tablet
- Fanapt 12 mg tablet
- Fanapt 1mg(2)-2 mg(2)-4mg(2)-6 mg(2) tablets in a dose pack
- Fanapt 2 mg tablet
- Fanapt 4 mg tablet
- Fanapt 6 mg tablet
- Fanapt 8 mg tablet
- lurasidone 120 mg tablet
- lurasidone 20 mg tablet
- lurasidone 40 mg tablet
- lurasidone 60 mg tablet
- lurasidone 80 mg tablet
- olanzapine 10 mg disintegrating tablet
- olanzapine 10 mg tablet
- olanzapine 15 mg disintegrating tablet
- olanzapine 15 mg tablet
- olanzapine 2.5 mg tablet
- olanzapine 20 mg disintegrating tablet
- olanzapine 20 mg tablet
- olanzapine 5 mg disintegrating tablet
- olanzapine 5 mg tablet
- olanzapine 7.5 mg tablet
- paliperidone ER 1.5 mg tablet,extended release 24 hr
- paliperidone ER 3 mg tablet,extended release 24 hr
- paliperidone ER 6 mg tablet,extended release 24 hr
- paliperidone ER 9 mg tablet,extended release 24 hr
- quetiapine 100 mg tablet
- quetiapine 150 mg tablet
- quetiapine 200 mg tablet
- quetiapine 25 mg tablet
- quetiapine 300 mg tablet
- quetiapine 400 mg tablet
- quetiapine 50 mg tablet
- quetiapine ER 150 mg tablet,extended release 24 hr
- quetiapine ER 200 mg tablet,extended release 24 hr
- quetiapine ER 300 mg tablet,extended release 24 hr
- quetiapine ER 400 mg tablet,extended release 24 hr
- quetiapine ER 50 mg tablet,extended release 24 hr
- Rexulti 0.25 mg tablet
- Rexulti 0.5 mg tablet
- Rexulti 1 mg tablet
- Rexulti 2 mg tablet
- Rexulti 3 mg tablet
- Rexulti 4 mg tablet
- risperidone 0.25 mg disintegrating tablet
- risperidone 0.25 mg tablet
- risperidone 0.5 mg disintegrating tablet
- risperidone 0.5 mg tablet
- risperidone 1 mg disintegrating tablet
- risperidone 1 mg tablet
- risperidone 1 mg/mL oral solution
- risperidone 2 mg disintegrating tablet

- risperidone 2 mg tablet
- risperidone 3 mg disintegrating tablet
- risperidone 3 mg tablet
- risperidone 4 mg disintegrating tablet
- risperidone 4 mg tablet
- Vraylar 1.5 mg capsule
- Vraylar 3 mg capsule
- Vraylar 4.5 mg capsule
- Vraylar 6 mg capsule
- ziprasidone 20 mg capsule
- ziprasidone 40 mg capsule
- ziprasidone 60 mg capsule
- ziprasidone 80 mg capsule

Details

| | |
|-----------------|--|
| Criteria | If the patient has tried two Step 1 drugs (oral formulations of Aripiprazole, Asenapine Maleate, Brexpiprazole, Cariprazine HCl, Lumateperone Tosylate, Lurasidone HCl, Olanzapine, Paliperidone, Quetiapine Fumarate, Risperidone, or Ziprasidone HCl), approve Fanapt. [Note: A trial of the brand name equivalent of a generic step 1 product will also count towards this requirement.] Approve if the patient is currently taking Fanapt or has taken Fanapt in the past. |
|-----------------|--|

DEXTROMETHORPHAN/BUPROPION

Products Affected

- Auvelity 45 mg-105 mg tablet, extended release
- bupropion HCl 100 mg tablet
- bupropion HCl 75 mg tablet
- bupropion HCl SR 100 mg tablet, 12 hr sustained-release
- bupropion HCl SR 150 mg tablet, 12 hr sustained-release
- bupropion HCl SR 200 mg tablet, 12 hr sustained-release
- bupropion HCl XL 150 mg 24 hr tablet, extended release
- bupropion HCl XL 300 mg 24 hr tablet, extended release
- citalopram 10 mg tablet
- citalopram 10 mg/5 mL oral solution
- citalopram 20 mg tablet
- citalopram 40 mg tablet
- desvenlafaxine succinate ER 100 mg tablet, extended release 24 hr
- desvenlafaxine succinate ER 25 mg tablet, extended release 24 hr
- desvenlafaxine succinate ER 50 mg tablet, extended release 24 hr
- duloxetine 20 mg capsule, delayed release
- duloxetine 30 mg capsule, delayed release
- duloxetine 40 mg capsule, delayed release
- duloxetine 60 mg capsule, delayed release
- escitalopram 10 mg tablet
- escitalopram 20 mg tablet
- escitalopram 5 mg tablet
- escitalopram 5 mg/5 mL oral solution
- fluoxetine 10 mg capsule
- fluoxetine 20 mg capsule
- fluoxetine 20 mg/5 mL (4 mg/mL) oral solution
- fluoxetine 40 mg capsule
- fluvoxamine 100 mg tablet
- fluvoxamine 25 mg tablet
- fluvoxamine 50 mg tablet
- nefazodone 100 mg tablet
- nefazodone 150 mg tablet
- nefazodone 200 mg tablet
- nefazodone 250 mg tablet
- nefazodone 50 mg tablet
- paroxetine 10 mg tablet
- paroxetine 10 mg/5 mL oral suspension
- paroxetine 20 mg tablet
- paroxetine 30 mg tablet
- paroxetine 40 mg tablet
- paroxetine ER 12.5 mg tablet, extended release 24 hr
- paroxetine ER 25 mg tablet, extended release 24 hr
- paroxetine ER 37.5 mg tablet, extended release 24 hr
- sertraline 100 mg tablet
- sertraline 20 mg/mL oral concentrate
- sertraline 25 mg tablet
- sertraline 50 mg tablet
- venlafaxine 100 mg tablet
- venlafaxine 25 mg tablet
- venlafaxine 37.5 mg tablet
- venlafaxine 50 mg tablet
- venlafaxine 75 mg tablet
- venlafaxine ER 150 mg capsule, extended release 24 hr
- venlafaxine ER 37.5 mg capsule, extended release 24 hr
- venlafaxine ER 75 mg capsule, extended release 24 hr
- vilazodone 10 mg tablet
- vilazodone 20 mg tablet
- vilazodone 40 mg tablet

Details

| | |
|-----------------|---|
| Criteria | Approve if the patient has tried a generic SSRI OR SNRI AND separately tried bupropion. Approve Auvelity if the patient has suicidal ideation without a trial of a Step 1 drug. Approve Auvelity if the patient is currently taking Auvelity or has taken Auvelity in the past. |
|-----------------|---|